Results
Proportions of TCZ patients who achieved JIA ACR30 + absence of fever or JIA ACR70/90 progressively improved from wk 12 to wk 52 (Table) . Number (mean ±SD) of joints with active arthritis or with limited range of motion decreased from 19.8±15.7 and 19.8±15.6, respectively, at baseline to 3.0±7.0 and 7.5±11.7, respectively, at wk 52, with 45% of patients having 0 active joints. At baseline, 55% of patients (n=62) had fever (temperature ≥37.5°C in the preceding 14 days), while at wk 52 only 9% (n=8) had fever. From baseline to wk 52, improvement in the scores was: CHAQ-DI from 1.7±0.9 to 0.7±0.8; physician global assessment VAS from 64.9 ±22.3 to 9.7±12.8, and patient/parent global assessment VAS from 58.7±24.4 to 12.6±18.5. There was a marked reduction in CS dose from 0.30±0.20 mg/kg/d at baseline to 0.06±0.08 at wk 52, with 48% having discontinued CS. There were 33 serious AEs (SAEs) in 25 patients; 12 SAEs were considered related (remote, possible, or probable) to TCZ (SAE rate: 0.23/patient year [PY] in part 1, 0.25/PY in part 2). Among the 15 serious infections, 6 were considered related to TCZ; all resolved and none led to study discontinuation. Twelve patients withdrew: 4 because of AEs; 4 because of insufficient response, 3 withdrew consent or did not return, and 1 died of a suspected tension pneumothorax unrelated to treatment.
Conclusion
Year 1 results from this first global phase 3 study demonstrate that TCZ is highly effective and generally well tolerated in patients with sJIA.
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